Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Munich, Germany, Tuesday 2 September 2008:
Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability
A twelve month study of treatment with darapladib concluded that, Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability. These findings suggest that Lp-PLA2 inhibition may represent a novel therapeutic approach. In contrast, despite adherence to a high level of standard of care treatment, necrotic core continued to expand among patients receiving a placebo.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is expressed abundantly in the necrotic core of coronary lesions and products of its enzymatic activity may contribute to inflammation and cell death, rendering plaque vulnerable to rupture.
This study compared the effects of 12 months of treatment with darapladib (oral Lp-PLA2 inhibitor, 160 mg daily) or placebo on coronary atheroma deformability (IVUS-palpography) and plasma hs-CRP in 330 patients with angiographically documented coronary disease. Secondary end points included changes in necrotic core size (IVUS-radiofrequency), atheroma size (IVUS-greyscale), and blood biomarkers.
Background therapy was comparable between groups, with no difference in LDL-cholesterol at 12 months (placebo: 88±34 and darapladib: 84±31 mg/dL, p=0.37). In contrast, Lp-PLA2 activity was inhibited by 59% with darapladib (p0.001 versus placebo). After 12 months, there were no significant differences between groups in plaque deformability (p=0.22) or plasma hsCRP (p=0.35). In the placebo-treated group, however, necrotic core volume increased significantly (4.5±17.9 mm3, p=0.009), whereas darapladib halted this increase (-0.5±13.9 mm3, p=0.71), resulting in a significant treatment difference of -5.2 mm3 (p=0.012). These intra-plaque compositional changes occurred without a significant treatment difference in total atheroma volume (p=0.95).
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2008. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved